APRI Share Price

Open 1.63 Change Price %
High 1.70 1 Day 0.04 2.45
Low 1.62 1 Week 0.00 0.00
Close 1.67 1 Month -0.18 -9.73
Volume 167835 1 Year -0.45 -21.23
52 Week High 4.07
52 Week Low 0.86
APRI Important Levels
Resistance 2 1.74
Resistance 1 1.71
Pivot 1.66
Support 1 1.63
Support 2 1.60
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

Apricus Biosciences, Inc (NASDAQ: APRI)

APRI Technical Analysis 1.5
As on 31st Oct 2017 APRI Share Price closed @ 1.67 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.65 & Sell for SHORT-TERM with Stoploss of 1.70 we also expect STOCK to react on Following IMPORTANT LEVELS.
APRI Target for June
1st Target up-side 1.96
2nd Target up-side 2.16
3rd Target up-side 2.36
1st Target down-side 1.38
2nd Target down-side 1.18
3rd Target down-side 0.98
APRI Other Details
Segment EQ
Market Capital 87012616.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.apricusbio.com
APRI Address
11975 El Camino Real
Suite 300
San Diego, CA 92130
United States
Phone: 858-222-8041
Fax: 858-436-8155
APRI Latest News
Interactive Technical Analysis Chart Apricus Biosciences, Inc ( APRI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Apricus Biosciences, Inc
APRI Business Profile
Apricus Biosciences, Inc., incorporated on October 20, 1987, is in the pharmaceutical industry primarily focusing on research and development using its drug delivery technology called NexACT. The Company is actively engaged in acquiring companies and in-licensing drugs that will complement its product portfolio.The Company's pipeline of approved and late stage NexACT based product candidates includes Vitaros, which is approved in Canada for the treatment of erectile dysfunction, Femprox for female sexual arousal disorder, MycoVa for onychomycosis excluding tinea pedis (nail fungal infection), RayVa for Raynaud’s Syndrome and PrevOnco for liver cancer. The Company's pipeline of late stage preclinical products includes Nupen for post-chemotherapy recovery of Neutrophil. In June, 2011, the Company sold Bio-Quant, Inc. (Bio-Quant). On December 29, 2011, the Company acquired Topotarget USA, Inc. In April 2013, the Company announced the sale of Totect (dexrazoxane HCl), and NitroMist (nitroglycerin sublingual aerosol). The Company owns or co-promotes five products: Vitaros for erectile dysfunction, Totect for anthracycline extravasation, NitroMist for acute relief of an attack or acute prophylaxis of angina pectoris (chest pain) due to coronary artery disease (narrowing of the blood vessels that supply blood to the heart), Granisol for the prevention of (i) nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin and nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation, and Aquoral for Xerostomia, the medical term for dry mouth due to a lack of saliva. The Company’s Totect (dexrazoxane HCl) is for the treatment of anthracycline extravasation, which is the leaking of chemotherapy from the veins of cancer patients into tissues and other areas of the body. The Company entered into a number of license and partnership agreements with pharmaceutical companies to market Vitaros for erectile dysfunction in the countries: Canada, United States, Italy, Germany, the Gulf countries and part of the Middle East and Israel. In January 2012, it signed a commercialization partnership in Canada with Abbott Laboratories, Ltd. (Abbott). Under the terms of agreement, Abbott will commercialize and market Vitaros in Canada. On February 22, 2012, it entered into a Clinical Supply Agreement with Warner Chilcott Company, Inc., (Warner Chilcott) to supply them with certain quantities of Vitaros.. On February 15, 2012, it signed a license and collaboration agreement with Sandoz, a division of Novartis, for Germany to market Vitaros in Germany for the treatment of erectile dysfunction.